ImmunityBio, Inc. — Director's Dealing 2025

Jan 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2025-01-22

Reporting Person: Simon Barry J. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-22	Common Stock	M	110020	$1.9984	Acquired	3233781	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-22	Stock Option (right to buy)	$1.9984	M	110020	Disposed	2025-02-16	Common Stock (110020)	Direct

Footnotes

F1: Cash exercise of options scheduled to expire on February 16, 2025.

F2: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option was January 16, 2015.